Neurogene Inc. announced its fourth quarter and full year 2024 financial results on March 24, 2025, reporting a net loss of $75.144 million for the full year, compared to $36.317 million in 2023. Research and development expenses for the full year 2024 increased to $60.917 million from $44.394 million in 2023, driven by the NGN-401 program.
The company also highlighted that NGN-401 for Rett syndrome received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA). This designation is intended to facilitate enhanced communication and potentially accelerate development and review processes in Europe.
In a separate filing on March 24, 2025, Neurogene Inc. filed for a mixed shelf offering of up to $300 million. This filing provides the company with financial flexibility to raise additional capital in the future, supporting its ongoing clinical development and operational needs, and reiterates a cash runway into the second half of 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.